Related Experiment Video
Updated: Jun 7, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable
Ricky Frazer1, José Ángel Arranz2, Sergio Vázquez Estévez3
1Velindre Cancer Centre, Cardiff, CF14 2TL, UK. ricky.frazer@wales.nhs.uk.
Purpose Of Review:
In this review, we discuss which patients with metastatic clear cell renal cell carcinoma (mRCC) may be most suitable for frontline tyrosine kinase inhibitor (TKI) monotherapy, a treatment option supported by emerging long-term efficacy data including overall survival and quality of life. We specifically focus on tivozanib, a potent and selective inhibitor of vascular endothelial growth factor receptor, which has comparable efficacy to other single-agent TKIs in frontline treatment for mRCC while exhibiting fewer off-target side effects.
Recent Findings:
Combination therapy with TKIs and checkpoint inhibitors (CPIs) and CPI/CPI combination therapies, as well as TKI monotherapy are recommended frontline treatment options for mRCC. Treatment decisions are complex and based on several factors, including the patient's International Metastatic RCC Database Consortium risk status, age, comorbidities, and personal preferences related to response, tolerability, and quality of life. TKIs not only serve as backbone of most combination therapies for mRCC, but also remain a viable monotherapy option in the first-line setting for patients in favorable risk groups and those with contraindications to CPI combination therapies. Given that overall survival benefits have not yet been confirmed for CPI-containing combination regimens in favorable risk patients, we argue that frontline single-agent TKI treatment remains a standard of care option for these patients. This is supported by treatment guidelines, even in the era of TKI/CPI combination therapies.
Insights
Frontline tyrosine kinase inhibitor (TKI) monotherapy is a viable option for select metastatic clear cell renal cell carcinoma (mRCC) patients, offering comparable efficacy and better tolerability than combination therapies, especially for favorable-risk groups.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic clear cell renal cell carcinoma (mRCC) treatment landscape includes combination therapies and tyrosine kinase inhibitor (TKI) monotherapy.
- TKI monotherapy, particularly with tivozanib, offers a potent and selective option with manageable side effects.
Purpose of the Study:
- To identify patient profiles suitable for frontline TKI monotherapy in mRCC.
- To evaluate the role of TKI monotherapy in light of emerging long-term efficacy data and combination treatment options.
Main Methods:
- Review of current treatment guidelines and emerging efficacy data for frontline mRCC therapies.
- Analysis of factors influencing treatment decisions, including risk status, patient comorbidities, and quality of life.
Main Results:
- TKI monotherapy is a recommended frontline option for mRCC, especially for favorable-risk patients and those with contraindications to checkpoint inhibitor (CPI) combinations.
- Tivozanib demonstrates comparable efficacy to other single-agent TKIs with a favorable side effect profile.
- Overall survival benefits of CPI-containing regimens are not yet confirmed in favorable-risk patients, supporting TKI monotherapy's continued role.
Conclusions:
- Frontline TKI monotherapy remains a standard of care for specific mRCC patient populations.
- Treatment decisions should be individualized based on risk status, comorbidities, and patient preferences for response and tolerability.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...